Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on November 12, 2019. The filing addresses an extension of the expiration date for previously announced Exchange Offers and Consent Solicitations related to notes issued by Celgene Corporation ("Celgene Notes"). These actions are directly tied to Bristol-Myers Squibb's planned acquisition of Celgene (the "Merger").
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The only specific financial figure disclosed relates to the scope of the debt exchange:
- Aggregate Principal Amount of New Notes: Up to $19,850,000,000.
The filing text does not provide a clear value for the company's current debt load, cash position, or operating results.
Material Changes
The primary material change reported is the extension of the deadline for the Exchange Offers and Consent Solicitations:
- Previous Expiration Date: November 13, 2019, at 5:00 p.m. New York City time.
- New Expiration Date: November 15, 2019, at 5:00 p.m. New York City time.
- Reason for Change: The Merger closing is expected to occur by the end of 2019, necessitating the extension to align the settlement date with the Merger closing.
Outlook, Risks, and Management Commentary
Management Commentary and Outlook:
- The settlement of the Exchange Offers is expected to occur promptly after the Expiration Date and on or about the closing date of the Merger.
- The Merger closing is targeted for the end of 2019.
- The Expiration Date may be further extended one or more times if necessary, with advance notice provided by the company.
Conditions and Risks:
- The Exchange Offers and Consent Solicitations are strictly conditioned upon the closing of the Merger; this condition cannot be waived by Bristol-Myers Squibb.
- Supplemental indentures executed on May 1, 2019, to eliminate restrictive covenants and certain events of default in the Celgene Notes will only become operative upon the settlement date of the Exchange Offers.
Key Facts for Investor Verification
- Verify the final closing date of the Bristol-Myers Squibb and Celgene Merger to confirm if the November 15, 2019 deadline requires further extension.
- Confirm the final aggregate principal amount of Celgene Notes exchanged for new Bristol-Myers Squibb notes and cash.
- Monitor for the execution of supplemental indentures to ensure the elimination of restrictive covenants in the Celgene Notes becomes operative.
- Review the attached press release (Exhibit 99.1) for detailed terms of the Exchange Offers and Consent Solicitations.